Navigation Links
Agendia Brings Together Thought Leaders in Molecular Diagnostics and Medical Oncology
Date:8/29/2012

IRVINE, Calif. and AMSTERDAM, Aug. 29, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, conducted one of its premiere thought leadership events, "Present and Future Trends in Breast Cancer Genomics," on Saturday, August 25, 2012. The event was held at The Westin Times Square Hotel in New York City and featured over 200 attendees that included leading medical oncologists, pathologists, surgeons and molecular biologists. The conference is one of several events organized by Agendia throughout the year that brings together research scientists and physicians in clinical practice dedicated to the use and development of molecular diagnostics for cancer treatment.

"Events like these demonstrate why it is an exciting time in the field of medical oncology," said Dr. Stefan Gluck, Chairman of Agendia's Medical Advisory Board. "Breakthrough tools in molecular diagnostics, such as Agendia's MammaPrint, BluePrint and ColoPrint, play an integral role in helping physicians make clinical decisions about how to most effectively treat their patients. Most importantly, these tools are only the beginning of the precision medicine revolution."

The event featured an impressive list of speakers and panels on the following topics:

The Science Behind Genomic Based Analysis of Breast Cancer

  • Rene Bernards, PhD
    Chief Scientific Officer and Co-Founder, Agendia

Clinical Utility of Molecular Diagnostics

  • Ralph V. Boccia, MD, FACP
    Clinical Associate Professor of Medicine, Georgetown University

Landmark Clinical Trials

  • Stefan Gluck, MD, FRCP(C), PhD
    Sylvester Professor, Miller School of Medicine, University of Miami

Tumor Round Table Discussion and Case Study Review

  • Stephanie Akbari, MD, FACS (Moderator)
    Medical Director, Center for Breast Health, Virginia Hospital Center
  • Mark A. Gittleman, MD, FACS
    Medical Director, Breast Care Specialists and Advanced Breast Care Imaging
  • Stefan Gluck, MD, PhD
    Sylvester Professor, Miller School of Medicine, University of Miami
  • James V. Pellicane, MD, FACS
    Director, Breast Oncology, Bon Secours Cancer Institute
  • Jamie Shutter, MD
    Owner, South Beach Medical Consultants
  • Hatem Soliman, MD
    Assistant Member, Comprehensive Breast Cancer and Experimental Therapeutics, Moffitt Cancer Center and Research Institute

"Seventy five percent of cancer therapies today are ineffective," said David Macdonald, CEO of Agendia. "This represents 37 billion dollars spent globally on cancer drugs that do not benefit patients. Today's event further demonstrates Agendia's commitment to the continued development of clinically reliable diagnostics that provide doctors with decision-making tools needed to improve the effectiveness of cancer therapies for their patients."

About Agendia:
Agendia is a leading molecular diagnostic company that develops and markets genomic-based diagnostic products, which help support physicians with their complex treatment decisions. Agendia's breast cancer Symphony™ suite was developed using unbiased gene selection, analyzing the complete human genome, ensuring 100% definitive results for cancer patients.  Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint­­, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, an alternative therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.

For more information, please visit www.agendia.com.

For further information, please contact:
Post+Beam
Melissa Hurley
Tel: +1 646 442 2773
E-mail: hurley@postandbeam.is


'/>"/>
SOURCE Agendia
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Earns ISO Certification for Facilities in Amsterdam and Irvine
2. Agendia Names Industry Veteran Glen Fredenberg CFO and Vice President of Finance
3. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
4. Power Wheelchair Brings Independence and Hope to Man with Complications Due to Spina Bifida
5. Transitions Optical Brings Importance Of Healthy, Enhanced Vision Into Focus By Taking National Sightseeing City Tour To Chicago And Announcing The Citys Top 10 Sights To See
6. Health Diagnostic Laboratory, Inc. (HDL, Inc.) Brings Advanced Testing to Capitol Hill, Discusses Health Care Cost Savings and Quality Improvement Potential
7. Cardinal Health Brings Resolution to Litigation with DEA Settlement
8. Industry Veteran Brings Sales Expertise to AlloSources Growing Distribution Network
9. Latest Breakthroughs and Treatments in Spinal Cord Injury Medicine Bring Top Clinicians and Researchers Together in Las Vegas
10. New Program Has Doctors, Patients Learn Together As Traditional Relationship Changes Forever
11. SuccessEHS "Forward Together" Customer Conference Begins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Research and Markets has announced the addition of ... Markets and Companies" to their offering. ... , , ... The market value of drug delivery technologies and the anticancer drugs ... according to organs involved and the types of cancer as well ...
(Date:12/2/2016)... Conn. , Dec. 1, 2016  Today, Simpson ... announced the honor of being selected as winners of ... Simpson Healthcare Executives Website at the PLATINUM level, Blue ... Training Module at the GOLD Level, and our proprietary ... At Simpson Healthcare Executives, we are excited to ...
(Date:12/2/2016)... Dec. 2, 2016  UCB is pleased to announce that 12 ... upcoming 70 th American Epilepsy Society (AES) Annual Meeting, ... TX , USA. 1-12 Data ... profile of VIMPAT ® (lacosamide) CV and BRIVIACT ® ... on the current state of the union of epilepsy care ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to ... and other developmental disabilities. The group, which is being launched with the help of ... to share stories and advice, seek help, and continue their education on how to ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. ... will be included in the 2016 “Guide to America’s Top Plastic Surgeons” for ... the amalgamation of their education, experience, and professional associations. , One the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... diagnostic imaging systems and the first company to offer robotic imaging to ... at their tradeshow booth # 941 for the American Association of Equine Practitioners ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... announce that we have been designated as a Cigna Infertility Center of Excellence. ... rigorous performance standards. , “It’s an honor to be designated a Cigna ...
Breaking Medicine News(10 mins):